股价异动，昭衍新药称不存在应披露而未披露的重大信息

Core Viewpoint - The stock of Zhaoyan New Drug (603127) experienced an abnormal trading fluctuation, with a cumulative price increase exceeding 20% over three consecutive trading days [1] Group 1: Stock Performance - The stock price increased significantly on March 27, March 30, and March 31, leading to a cumulative price deviation of over 20% [1] - The abnormal trading situation is in accordance with the regulations of the Shanghai Stock Exchange [1] Group 2: Company Response - Zhaoyan New Drug conducted a self-examination and consulted with its controlling shareholder and actual controller, confirming that there are no undisclosed significant information as of the announcement date [1] - The company advises investors to be cautious of market trading risks and to make rational investment decisions [1]